Top View
- Tebipenem: a Novel Oral Carbapenem Archana Mahalingam1, Bhaskar Shenoy2
- Tebipenem an Oral Carbapanem with Activity Against Multi-Drug Resistant
- Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem Hbr
- The Bacterial Challenge: Time to React
- Against Penicillin-Binding Proteins of Gram-Negative Bacteria E
- Successful Use of Repurposed Drugs for MDR TB: Meropenem/Clavulanate and Its Newer Rela Ves
- Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation Against a Variety of Pathogenic Bacteria in Vitro and in Vivo
- New Β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the in Vitro Activity Of
- Tebipenem, the First Oral Carbapenem Antibiotic
- From Evidence to Clinical Guidelines in Antibiotic Treatment in Acute Otitis Media in Children
- Elizabeth T. Escaño-Gallardo, MD, FPPS, FPIDSP 23Rd Annual Convention Pediatric Infectious Disease Society of the Philippines February 19, 2016 Objectives
- Antibiotics in the Clinical Pipeline in October 2019
- SPR994: Oral Carbapenem for the Treatment of Complicated Urinary Tract Infections
- New ATC Codes and New Ddds to Be Included in the 2019 Edition of the ATC/DDD Index Are Also Enclosed
- Risk of Hypoglycemia Induced by Pivalate-Conjugated Antibiotics in Young Children: A
- K. Pneumoniae
- Amc Data 2011–2017
- Lactamase Producing ESKAPE Pathogens
- BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances 2009
- Of M/S. Covalent Laboratories Pvt. Ltd., Unit-I
- In Vitro and in Vivo Activity of Tebipenem Against ESBL-Producing E
- Old Antibiotics As Alternative Treatment Options for Urinary Tract Infections Caused by ESBL-, Ampc- and Carbapenemase-Producing Escherichia Coli
- Novel Prodrugs of Meropenem with Two Lipophilic Promoieties: Synthesis and Pharmacokinetics
- Corporate Presentation
- 2019 Asm Escmid Abstracts for Poster Presentations
- Antimicrobial Medicines Consumption in Eastern Europe and Central Asia – an Updated Cross-National Study and Assessment of Quantitative Metrics for Policy Action
- Global Longitudinal Assessment of 2019 Changes in Defined Daily Doses
- Antibiotics in the Clinical Pipeline in 2013
- Impact of Commonly Used Antimicrobial Biocides on Resistance and Cross-Resistance in Carbapenemase-Producing Enterobacteriaceae
- Table 2 MIC Distributions of Tebipenem Tested Against Specific Phenotypes
- New Carbapenemase Inhibitors: Clearing the Way for the -Lactams
- PK/PD) Index Map for Selecting an Optimal PK/PD Index from Conventional Indices
- Assessment of Activity of a Novel Orally Bioavailable Β-Lactam/Β-Lactamase Inhibitor Combination, Ceftibuten/VNRX-7145